Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Mild Cognitive Impairment, So Stated
Interventions
DRUG

AL-108

5 mg QD

DRUG

AL-108

15 mg BID

DRUG

Placebo

Placebo

Trial Locations (17)

11235

SPRI Clinical trials, Brooklyn

28405

Memory Assessment and Research Services, Wilmington

32216

Clinical Neuroscience Solutions, Inc., Jacksonville

32806

Clinical Neuroscience Solutions, Orlando

32960

Clinical Research Center of Indian River Medical Center, Vero Beach

33606

Meridien Research, Tampa

33613

Stedman Clinical Trials, Tampa

34613

Meridien Research, Brooksville

38119

Clinical Neuroscience Solutions, Inc, Memphis

43623

Neurology & Neuroscience Center of Ohio, Toledo

60194

Comprehensive Neuroscience, Hoffman Estates

78757

Senior Adults Speciality Research, Austin

85381

Pivotal Research, Peoria

91950

Synergy Research, National City

92103

Pacific Research Network, Inc, San Diego

92845

Collaborative Neuroscience Network, Garden Grove

07740

The Memory Enhancement Center of America, Long Branch

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allon Therapeutics

INDUSTRY

NCT00422981 - Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment | Biotech Hunter | Biotech Hunter